Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer

European Journal of Cancer

Volumn 35, Issue 8, 1999, Pages 1214-1219

  Mano, Y ^a   Kikuchi, Y ^a   Yamamoto, K ^a   Kita, T ^a   Hirata, J ^a   Tode, T ^a   Ishii, K ^a   Nagata, I ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Apoptosis; bcl 2; Cisplatin; Cisplatin resistance; MDM 2; Ovarian cancer; p53

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032794804     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00124-0     Document Type: Article

References (23)

1. Dive C., Hickman J.A. Drug-target interactions. only the first step in the commitment to programmed cell death Br. J. Cancer. 64:1991;192-196.
2. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442.
3. Halder S., Jena N., Dubois G.et al. Purification and characterization of the bcl-2 protein. Arch. Biochem. Biophys. 315:1994;483-488.
4. Miyashita T., Reed J. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 11:1993;151-157.
5. Carson D.A., Ribeiro J.M. Apoptosis and disease. Lancet. 341:1993;1251-1254.
6. Pietenpol J.A., Papadopoulos N., Markowitz S., Wilson J.K.V., Kinzler K.W., Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res. 54:1994;3714-3717.
7. Maestro R., Dolcetti R., Gasparotto D.et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene. 7:1992;1159-1166.
8. Wynford-Thomas D. p53 in tumour pathology. can we trust immunocytochemistry? J. Pathol. 166:1992;329-330.
9. Perry M.E., Piette J., Zawadzki J.A., Harvey D., Levine A.J. The mdm-2 gene is induced in response to UV light in a p53-dependent. Proc. Natl. Acad. Sci. USA. 90:1993;11623-11627.
10. Chen C-Y., Oliner J.D., Zhan Q., Fornance A.J., Vogelstein B., Kastan M.B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA. 91:1994;2684-2688.
11. Bauer J.J., Sesterhenn I.A., Mostofi F.K., Mcleod D.G., Srivastava S., Moul J.W. Elevated levels of apotosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol. 156:1996;1511-1516.
12. Diebold J., Baretton G., Felchner M.et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am. J. Clin. Pathol. 105:1996;341-349.
13. Sinicrope F.A., Evans D.B., Leach S.D.et al. Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas. association with clinical outcome Clin. Cancer Res. 2:1996;2015-2022.
14. Manne U., Myers R.B., Moron C.et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int. J. Cancer. 74:1997;346-358.
15. Herod J.J.O., Eliopoulos A.G., Warwick J.et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 56:1996;2178-2184.
16. Moman J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
17. Kondo S., Barnett G.H., Hara H., Morimura T., Takeuchi J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene. 10:1995;2001-2006.
18. Makar A.P., Baekelandt M., Tropé C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56:1995;175-180.
19. Marx D., Meden H., Ziemek T., Lenthe T., Kuhn W., Schauer A. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur. J. Cancer. 34:1998;845-850.
20. Henriksen R., Wilander E., Öberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br. J. Cancer. 72:1995;1324-1329.
21. Willingham M.C., Bhalla K. Transient mitotic-phase localization of Bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis. J. Histochem. Cytochem. 42:1994;441-450.
22. Lu Q.L., Hanby A.M. Bcl-2 protein localizes to the chromosomes of mitotic nuclei and is correlated with the cell cycle in cultured epithelial cell lines. J. Cell Sci. 107:1994;363-371.
23. Sakuragi N., Ohkouchi T., Hareyama H.et al. Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int. J. Cancer. 79:1998;153-158.